At Novo Nordisk, we are driving change to defeat diabetes and other serious chronic conditions.
Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity.
Headquartered in Denmark, Novo Nordisk employs approximately 42,200 employees in 80 countries, and markets its products in more than 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).
The purpose of this website is to inform healthcare professionals and members of the general public about Novo Nordisk and their products.
Information placed on this website is not intended as a substitute for consultation with your healthcare professional.
Date of preparation: April 2020
The Apis bull logo is a registered trademark owned by Novo Nordisk A/S
Our Updates during the COVID-19 pandemic
During the COVID-19 pandemic, our commitment to patients, our employees and the communities where we operate remains unchanged.
We will continue to supply our medicines to people living with diabetes and other serious chronic diseases, safeguard the health of our employees, and take actions to support doctors and nurses as they work to defeat COVID-19.
Statement from Novo Nordisk Ireland Limited:
Coronavirus (Covid-19) and the supply of Novo Nordisk medicinal products in Ireland
Novo Nordisk Limited
Block A, The Crescent Building
Northwood Business Park
Tel: +353 1 862 9700
Fax: +353 1 862 9725
Report a complaint or a side effect
Novo Nordisk cannot provide individual medical advice to the general public. For these type of queries individuals should contact their doctor, nurse or pharmacist.
If you have experienced a complaint or a side effect to a Novo Nordisk product, you should contact your local doctor or other medical health professional for advice. Information about complaints and side effects help us to ensure the safe use of our products and we encourage you to also report this to Novo Nordisk on 1850 665 665 or by email to firstname.lastname@example.org
Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL – Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie; E-mail: email@example.com